← All educational resources

Heparin and Prostaglandins: The Mast Cell Markers That Actually Turn Positive

2026-11-22

Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.

This is the third observation post, and it is about testing. In the people I have worked through a mast cell activation picture with, the two tests that doctors reach for first, serum tryptase and plasma histamine, almost never come back abnormal. The two that do are plasma heparin and the prostaglandin D2 metabolite in urine. I started noticing this years ago, and it turns out the published numbers agree, which is the part worth writing down.

Why tryptase and histamine miss

Tryptase is an enzyme stored in mast cell granules; histamine is the famous mediator. Both are released when mast cells degranulate. The trouble is timing and type.

Histamine is cleared from blood within minutes. By the time you have noticed the flush, driven to a lab, and had blood drawn, it is gone. The urine version (N-methylhistamine, collected over 24 hours) is better but still misses most activation.

Tryptase stays in blood for hours, so timing is less of a problem, but the baseline tryptase test was designed to find mastocytosis, a condition where there are too many mast cells. In mast cell activation syndrome the problem is not the number of mast cells but how easily they fire and what they release, and many of them release relatively little tryptase when they do. A normal tryptase rules out mastocytosis; it does not rule out activation. (A tryptase that is persistently over 8 ng/mL is a different signal: it can mean an extra copy of the tryptase gene, which is common and has its own symptom pattern.)

The consensus diagnostic criteria still lean on tryptase rising by 20 percent plus 2 during a reaction compared with baseline, which requires catching a reaction with a blood draw, which almost nobody manages.

Why heparin and prostaglandin D2 catch it

Mast cells are the body's main source of heparin, the anticoagulant. They also make prostaglandin D2 in large amounts (a mast cell makes far more PGD2 than other cells), which is cleared through a metabolite, 2,3-dinor-11-beta-PGF2-alpha, that can be measured in a 24-hour urine.

The published study that matches what I see is a 2015 German paper that measured plasma heparin in 257 patients with mast cell activation disease. In the mast cell activation syndrome group, baseline heparin was elevated in 41 percent, and in 59 percent after a simple provocation (a blood pressure cuff left inflated on the arm for ten minutes, which mechanically stresses the mast cells in that limb), versus tryptase elevated in only 10 percent, chromogranin A in 12 percent, and urinary N-methylhistamine in 22 percent. Combining heparin with the other markers found activation in up to 90 percent. In the mastocytosis patients the pattern flipped and tryptase was the best marker, which is exactly what you would expect: tryptase counts mast cells, heparin measures their activity.

The PGD2 metabolite has a similar story from the Mayo group: in patients with mast cell activation symptoms and normal tryptase, the urinary PGD2 metabolite was the most frequently elevated mediator, and it is the one that predicts a response to aspirin or other prostaglandin-blocking treatment.

So the two markers I was seeing turn positive are the two the literature says turn positive in activation without mastocytosis. The observation is not new; it is under-used.

Why the standard panel still misses it

Three reasons, all fixable.

  1. The test is not ordered. Plasma heparin for mast cell purposes is unfamiliar; most clinicians know heparin only as a drug level. The order is "plasma heparin, anti-Xa, no heparin therapy" in a citrated tube, kept cold, spun within 30 minutes. The PGD2 metabolite is a 24-hour urine from the big reference laboratories, kept cold throughout.
  2. The sample is handled wrong. Prostaglandins degrade at room temperature; the urine jug has to sit in the refrigerator or on ice the whole day. Heparin needs a chilled tube and prompt processing. A warm sample reads normal.
  3. The medication is not stopped. Antihistamines, NSAIDs, and aspirin lower the readings; where it is safe, antihistamines are held for 48 hours and NSAIDs and aspirin for five days before the collection. Proton pump inhibitors interfere with chromogranin A.

The panel I think is worth asking for

For someone with the symptom pattern (flushing, hives, itch, racing heart after food, reactions to wine and leftovers, bloating, anxiety, the 3 am wake-up, worse at ovulation and in heat):

  • Plasma heparin, ideally baseline and after the ten-minute cuff
  • 24-hour urine for N-methylhistamine and 2,3-dinor-11-beta-PGF2-alpha, kept cold
  • Chromogranin A (off acid blockers)
  • Serum tryptase, once, as the mastocytosis screen, with the gene copy test if it is over 8
  • The gut tests, because every mast cell client I have seen has had dysbiosis: a stool test and a breath test for bacterial overgrowth (the SIBO post here)

The lab guide here has the handling rules and the ranges, and the appointment checklist here has the one-paragraph version for the clinician.

What a positive result changes

A positive heparin or PGD2 metabolite does two things. It confirms that what you are feeling is mast cell mediator release, which ends the "it's anxiety" conversation. And it points at which treatment the research supports: the PGD2 metabolite specifically predicts response to aspirin-class drugs in the Mayo data (through a clinician, because aspirin triggers some mast cell patients), while heparin elevation tracks overall activity and is the one to recheck at three months to see whether the stabilizers, the diet, and the gut work have changed anything. The mast cell post here lays out that sequence.

How to test the observation

The claim is that in people with the symptom pattern and a normal tryptase, heparin and the PGD2 metabolite will be elevated far more often than histamine. Anyone with the pattern who gets the full panel can score it: which markers were abnormal and which were normal. Pooled through the People's Data Commons, a few dozen panels would say whether the 2015 numbers hold in a self-selected group, and whether the gut findings co-occur as consistently as I think they do.

Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. Test ordering, interpretation, and any trial of aspirin or other medication are decided by your clinician.

The observation

In a research consulting population with the clinical phenotype of mast cell activation syndrome (MCAS), serum tryptase and plasma histamine are rarely abnormal, while plasma heparin and urinary 2,3-dinor-11-beta-PGF2-alpha (the PGD2 metabolite) are frequently elevated. Every individual in this population evaluated for gut function has shown dysbiosis on stool or breath testing. The observation is uncontrolled; the published literature on mediator sensitivity supports the first part directly, which is the reason to set it out.

The diagnostic landscape

Two consensus frameworks exist. The consensus-1 criteria (Valent 2012, revised 2019) require typical symptoms in two or more organ systems, a transient tryptase increase of 20 percent plus 2 ng/mL above baseline within 4 hours of a reaction, and response to mediator-targeting therapy; these are designed for high specificity and anchor on tryptase. The consensus-2 criteria (Molderings, Afrin, and others; 2011, 2020) accept a broader mediator panel (tryptase, histamine and N-methylhistamine, PGD2 and its metabolites, heparin, chromogranin A, leukotriene E4) and clinical response, trading specificity for sensitivity. The debate between them is substantially a debate about which mediators to measure and how.

Why tryptase and histamine under-detect activation

Histamine has a plasma half-life of minutes; a sample drawn after the symptomatic episode has begun to resolve reads normal. Urinary N-methylhistamine integrates over the collection period and performs better, but in the Vysniauskaite series was elevated in only 22 percent of MCAS patients.

Tryptase has a half-life of about 2 hours and is a marker of mast cell burden more than of activation; baseline tryptase correlates with mast cell number (systemic mastocytosis) and with TPSAB1 copy number (hereditary alpha-tryptasemia, prevalence about 5 percent, baseline tryptase over 8 ng/mL, with its own multisystem phenotype). In non-clonal MCAS, mast cells may degranulate with modest tryptase release, or release lipid mediators and cytokines without full degranulation (piecemeal or selective release), and the required paired baseline and acute samples are rarely obtained. Baseline tryptase was elevated in 10 percent of MCAS patients versus 73 percent of systemic mastocytosis patients in the 2015 series.

Evidence for plasma heparin

Mast cells are the principal source of heparin in the body (stored in granules bound to proteoglycan cores; released on degranulation). Vysniauskaite and colleagues (PLoS ONE 2015; 257 patients: 238 MCAS, 19 systemic mastocytosis; 24 healthy controls) measured plasma heparin by chromogenic anti-factor Xa assay in CTAD tubes, chilled and processed within 30 minutes, at baseline and after a 10-minute venous occlusion (cuff inflated 10 mmHg above diastolic), corrected for hemoconcentration by fibrinogen. Sensitivity in MCAS: basal plasma heparin 41 percent, post-occlusion 59 percent, versus tryptase 10 percent, chromogranin A 12 percent, and urinary N-methylhistamine 22 percent; combinations reached up to 90 percent. In systemic mastocytosis the ordering reversed (tryptase 73 percent, heparin 27 to 47 percent), consistent with tryptase as a burden marker and heparin as an activity marker. Healthy controls showed no occlusion effect. Mediators did not correlate with one another, implying different release profiles across patients and arguing for a panel rather than a single marker. The same group has documented a bleeding diathesis in a subset of MCAS patients attributable to endogenous heparin.

Pre-analytic requirements: citrated (CTAD) tube, no heparin therapy, immediate chilling, centrifugation within 30 minutes, anti-Xa assay reported in IU/mL against the laboratory's own upper limit (0.02 to 0.05 IU/mL depending on assay).

Evidence for the PGD2 metabolite

Mast cells generate PGD2 via hematopoietic PGD synthase at roughly 100-fold the rate of other cells per unit; PGD2 is unstable and measured through its stable urinary metabolites (2,3-dinor-11-beta-PGF2-alpha, 11-beta-PGF2-alpha). The Mayo Clinic series (Ravi, Butterfield, and Weiler, 2014; Butterfield's subsequent work) found that among patients with mast cell activation symptoms and normal baseline tryptase, the urinary PGD2 metabolite was the most frequently elevated mediator, and that its elevation predicted clinical response to aspirin (a COX inhibitor, used cautiously because aspirin precipitates reactions in a subset, with graded introduction under supervision). Urinary leukotriene E4 is elevated in a further subset and predicts response to leukotriene antagonists. Pre-analytics: 24-hour collection kept refrigerated or on ice throughout; NSAIDs and aspirin withheld 5 days and antihistamines 48 hours where safe; creatinine normalization.

Chromogranin A

Released from mast cell granules and from neuroendocrine cells; elevated in 12 percent of MCAS in the 2015 series; confounded by proton pump inhibitors (marked elevation), renal impairment, and neuroendocrine tumors; useful in a panel, uninterpretable on a PPI.

The gut co-finding

Every MCAS individual in the observed population evaluated for gut function has shown dysbiosis (stool microbiome abnormality, SIBO on breath testing, or both). The literature supports a bidirectional relationship: mast cell density and activation are increased in SIBO and post-infectious IBS; histidine decarboxylase-expressing taxa generate luminal histamine; LPS and microbial metabolites activate mast cells via TLR4 and other receptors; mast cell mediators alter motility and permeability, perpetuating dysbiosis. Whether dysbiosis is upstream, downstream, or both in a given patient is not resolved, and the clinical implication is that gut assessment belongs in the MCAS work-up and that dietary histamine restriction (the low-histamine trial here) plateaus when enteric histamine production is not addressed (the SIBO post here).

A proposed panel

Test Sample and handling Hold Reads
Plasma heparin, basal and post 10-minute venous occlusion CTAD, chilled, spun within 30 minutes; anti-Xa None (not on heparin) Activation
24-hour urinary N-methylhistamine and 2,3-dinor-11-beta-PGF2-alpha (add LTE4 where available) Refrigerated throughout; creatinine-normalized Antihistamines 48 h, NSAIDs and aspirin 5 d, where safe Activation; PGD2 predicts aspirin response; LTE4 predicts antileukotriene response
Chromogranin A Serum PPIs 5 to 7 d Activation, with confounders
Serum tryptase Serum, once at baseline; paired acute sample if a reaction can be captured None Burden; over 8 ng/mL prompts TPSAB1 copy number; over 20 prompts mastocytosis evaluation (KIT D816V, bone marrow by hematology)
Stool analysis and breath test Per the SIBO post Antibiotics 4 w, probiotics 2 w The co-finding
Copper, ceruloplasmin, PLP, vitamin D Serum DAO and HNMT cofactors

What positivity changes

Mediator positivity converts a symptom-based impression into documented mast cell activity, which alters the clinical conversation and satisfies the mediator criterion of either consensus framework. Mediator profile guides therapy: PGD2-predominant patients are candidates for aspirin or other COX inhibition under supervised introduction; LTE4-predominant for montelukast or zafirlukast; histamine-predominant for H1 and H2 blockade and DAO support; heparin as the activity marker to repeat at 3 months to assess response to stabilization (cromolyn, ketotifen), dietary restriction, and gut treatment (the mast cell post here).

Testing the observation

The claim: in individuals with the MCAS phenotype and normal baseline tryptase, plasma heparin and the urinary PGD2 metabolite will be elevated substantially more often than histamine or N-methylhistamine, and dysbiosis will be found in the large majority. A pooled registry of complete panels through the People's Data Commons, scoring each marker as elevated or normal with handling documented, would reproduce or refute the 2015 sensitivities in a self-selected population and estimate the gut co-occurrence rate. Handling failures (warm samples, medication not held) are the expected source of false negatives and should be recorded.

Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. Test selection, interpretation, and any trial of aspirin, antileukotrienes, or mast cell stabilizers are decided by the treating clinician.